Serologic and Clinical Outcomes of 1536 Alaska Natives Chronically Infected with Hepatitis B Virus

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Annals of Internal Medicine

• Publication date

  2001-11-06

• Fields of study

  Medicine

• Identifiers
  DOI 10.7326/0003-4819-135-9-200111060-00006PMID 11694101
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Hepatitis B virions isolated with antibodies to the pre‐S1 domain reveal occult viremia by PCR in Alaska Native HBV carriers who have seroconverted

  2000cited by this paper
• HEPATITIS B IN ADULTS

  1999cited by this paper
• Use of Interferon for Prevention of Hepatocellular Carcinoma in Cirrhotic Patients with Hepatitis B or Hepatitis C Virus Infection

  1999cited by this paper
• A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

  1998cited by this paper
• Sero‐clearance of hepatitis B surface antigen in chronic carriers does not necessarily imply a good prognosis

  1998cited by this paper
• Hepatitis B virus infection.

  1998cited by this paper
• Molecular basis for persistent hepatitis B virus infection in the liver after clearance of serum hepatitis B surface antigen

  1998cited by this paper
• Spontaneous seroconversion in hepatitis B e antigen-positive chronic hepatitis B: implications for interferon therapy.

  1997cited by this paper
• Hepatitis B virus infection.

  1997cited by this paper
• Long‐term outcome of hepatitis B e antigen–positive patients with compensated cirrhosis treated with interferon alfa

  1997cited by this paper
• Viral hepatitis : diagnosis, treatment, prevention

  1997cited by this paper
• J. Virol. Methods

  1996cited by this paper
• Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B.

  1996cited by this paper
• Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: Incidence and prevalence of hepatocellular carcinoma in a North American urban population

  1995cited by this paper
• The significance of spontaneous hepatitis B e antigen seroconversion in childhood: With special emphasis on the clearance of hepatitis B e antigen before 3 years of age

  1995cited by this paper
• The Natural History of Asymptomatic Hepatitis B Surface Antigen Carriers

  1993cited by this paper
• Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B

  1993cited by this paper
• The natural history of asymptomatic hepatitis B surface antigen carriers.

  1993cited by this paper
• Seroprevalence of hepatitis B viral markers in 52,000 Alaska Natives.

  1993cited by this paper
• Clearance of HBsAg in seven patients with chronic hepatitis B

  1992cited by this paper
• Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver.

  1992cited by this paper
• Long-term remission of chronic hepatitis B after alpha-interferon therapy.

  1991cited by this paper
• Incidence, determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection: A prospective study

  1991cited by this paper
• Hepatitis B virus.

  1991cited by this paper
• Regional prevalence of hepatitis B, delta, and human immunodeficiency virus infection in southern Africa: a large population survey.

  1989cited by this paper
• Hepatitis B virus. The major etiology of hepatocellular carcinoma

  1988influential reference
• The development of cirrhosis in patients with chronic type B hepatitis: A prospective study

  1988cited by this paper
• A comprehensive programme to reduce the incidence of hepatitis B virus infection and its sequelae in Alaskan natives.

  1987cited by this paper
• Increased risk for lethal forms of liver disease among HBsAg-positive blood donors in the United States.

  1987cited by this paper
• Spontaneous hepatitis B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection.

  1987cited by this paper
• The hepatitis B carrier state--a follow-up study of 100 consecutive cases.

  1987cited by this paper
• Acute exacerbation in chronic type B hepatitis: Comparison between HBeAg and antibody‐positive patients

  1987cited by this paper
• Hepatocellular carcinoma among female Japanese hepatitis B virus carriers.

  1987cited by this paper
• Clinical, virologic and histologic outcome following seroconversion from HBeAg to anti‐HBe in chronic hepatitis type B

  1986cited by this paper
• Mortality of hepatitis B positive blood donors in England and Wales.

  1985cited by this paper
• Early detection of primary hepatocellular carcinoma. Screening for primary hepatocellular carcinoma among persons infected with hepatitis B virus.

  1985cited by this paper
• Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state.

  1985cited by this paper
• Spontaneous reactivation of chronic hepatitis B virus infection.

  1984cited by this paper
• Survival in chronic hepatitis B. An analysis of 379 patients.

  1984cited by this paper
• Clinical and histological events preceding hepatitis B e antigen seroconversion in chronic type B hepatitis.

  1983cited by this paper
• Prevalence of hepatitis B in selected Alaskan Eskimo villages.

  1983cited by this paper
• NATURAL HISTORY OF LIVER DISEASE IN CHRONIC HEPATITIS B SURFACE ANTIGEN CARRIERS: Survey of 100 Patients from Great Britain

  1981cited by this paper
• Natural history of liver disease in chronic hepatitis B surface antigen carriers. Survey of 100 patients from Great Britain.

  1981cited by this paper
• Seroconversion from hepatitis B e antigen to antibody in chronic type B hepatitis.

  1981cited by this paper
• A prospective study of hepatitis B virus serologic markers and liver enzymes.

  1980cited by this paper
• Epidemiology of hepatitis B in two Alaska communities.

  1977cited by this paper
• EPIDEMIOLOGY OF HEPATITIS B IN TWO ALASKAN COMMUNITIES

  1977cited by this paper

• Improving Survival Prediction of HIV Treatment Dropout with Group-Wise Self-Attention Network

  2025cites this paper
• Effect of Promoter Region Polymorphisms in the IP-10 Gene on HBsAg Loss in Chronic Hepatitis B Patients

  2025cites this paper
• Chronic Hepatitis B Virus Infection Acquired Under Cytostatic Treatment in Childhood — Clinical, Virological and Immunological Long‐Term Follow‐Up

  2025cites this paper
• Research Progress of Pegylated Interferon Therapy for Chronic HBV Infection

  2024cites this paper
• Hepatitis B Care Continuum Models-Data to Inform Public Health Action.

  2024cites this paper
• Expert Consensus on the Prevention and Treatment of Chronic Hepatitis B in Children

  2024cites this paper
• Functional cure of hepatitis B in patients with cancer undergoing immune checkpoint inhibitor therapy.

  2024cites this paper
• Effect of immune checkpoint inhibitors on patients with hepatitis B virus infection

  2024cites this paper
• Impact of fatty liver on long-term outcomes in chronic hepatitis B: a systematic review and matched analysis of individual patient data meta-analysis

  2023cites this paper
• Clinical Consequences of Hepatitis B Surface Antigen Loss in Chronic Hepatitis B Infection: A Systematic Literature Review and Meta-Analysis

  2023cites this paper
• Anti-HBc: a significant host predictor of spontaneous HBsAg seroclearance in chronic hepatitis B patients - a retrospective longitudinal study

  2023cites this paper
• Plasma interferon‐gamma‐inducible‐protein 10 level as a predictive factor of spontaneous hepatitis B surface antigen seroclearance in chronic hepatitis B patients

  2023cites this paper
• Non-invasive diagnosis of liver fibrosis in children with chronic hepatitis B by transient elastography

  2023cites this paper
• Cost Effectiveness of Implementing a Universal Birth Hepatitis B Vaccination Program in Ontario

  2023cites this paper
• Early clinical efficacy of pegylated interferon treatment in patients with different phases of chronic HBV infection: A real‐world analysis

  2022cites this paper
• Bile acids as drivers and biomarkers of hepatocellular carcinoma

  2022cites this paper
• Insights Into the Coinfections of Human Immunodeficiency Virus-Hepatitis B Virus, Human Immunodeficiency Virus-Hepatitis C Virus, and Hepatitis B Virus-Hepatitis C Virus: Prevalence, Risk Factors, Pathogenesis, Diagnosis, and Treatment

  2022cites this paper
• Feasibility of hepatitis B elimination in high-income countries with ongoing immigration.

  2022cites this paper
• Incidence of Hepatocellular Carcinoma and Decompensated Liver Cirrhosis and Prognostic Accuracy of the PAGE-B HCC Risk Score in a Low Endemic Hepatitis B Virus Infected Population

  2022cites this paper
• Hepatocellular Carcinoma in Hepatitis B Virus-Infected Patients and the Role of Hepatitis B Surface Antigen (HBsAg)

  2022cites this paper
• Al-Azhar Un. Journal for Research and Studies. Vol 4(1) March.2022

  2022cites this paper
• Analysis of the Efficacy and Safety of PEGylated Interferon-α2b Treatment in Inactive Hepatitis B Surface Antigen Carriers

  2021cites this paper
• Chronic Hepatitis B

  2021cites this paper
• Viral and Host Factors Affecting Disease Progression of Hepatitis B Virus Infection

  2021cites this paper
• Durability of hepatitis B surface antigen seroclearance and subsequent risk for hepatocellular carcinoma: A meta‐analysis

  2021cites this paper
• Differential characteristics and outcomes of Asian and non‐Asian patients with HBV‐related hepatocellular carcinoma

  2021cites this paper
• Hepatitis B in Children - The Pursuit of a Hepatitis Free Future Generation.

  2021cites this paper
• Systematic review with meta‐analysis: the impact of functional cure on clinical outcomes in patients with chronic hepatitis B

  2021cites this paper
• ANTXR1 as a potential prognostic biomarker for hepatitis B virus-related hepatocellular carcinoma identified by a weighted gene correlation network analysis.

  2021cites this paper
• Treatment of Chronic Hepatitis B Virus with Oral Anti-Viral Therapy.

  2021cites this paper
• Hepatocellular Carcinoma: Diagnosis and Surveillance

  2021cites this paper
• Hepatitis B: Who should be treated?-managing patients with chronic hepatitis B during the immune-tolerant and immunoactive phases

  2021cites this paper
• Guidelines for Prevention and Treatment of Chronic Hepatitis B

  2021cites this paper
• A preoperative nomogram predicts prognosis of patients with hepatocellular carcinoma after liver transplantation: a multicenter retrospective study

  2020cites this paper
• Assess the knowledge of dentists regarding Hepatitis B serological profile: a cross-sectional study.

  2020cites this paper
• Diagnostic Problems of Occult HBV Infection

  2020cites this paper
• JSH Guidelines for the Management of Hepatitis B Virus Infection: 2019 Update.

  2020cites this paper
• Predictive factors for risk of hepatocellular carcinoma in immune inactive chronic hepatitis B.

  2020cites this paper
• Experience with Hepatitis B Viral load Testing in Jharkhand

  2019cites this paper
• A Changing Era in Chronic Hepatitis B: Novel Biomarkers and Therapies

  2019cites this paper
• Role of HBsAg Testing in the Management of Patients with Chronic HBV

  2019cites this paper
• Preventing Hepatitis B in the Dialysis Unit.

  2019cites this paper
• Cost-Effectiveness of Tenofovir Alafenamide for Treatment of Chronic Hepatitis B in Canada

  2019cites this paper
• Diagnostic value of gamma-glutamyltransferase/aspartate aminotransferase ratio, protein induced by vitamin K absence or antagonist II, and alpha-fetoprotein in hepatitis B virus-related hepatocellular carcinoma

  2019cites this paper
• Hepatitis B Virus Infection and the Progress toward its Elimination

  2019cites this paper
• MicroRNAs Biomarkers Profiling  in Diagnosis and Therapeutic Management of Hepatitis B Virus Infection

  2019cites this paper
• Hepatitis B virus infection in children and adolescents.

  2019cites this paper
• Spontaneous loss of surface antigen among adults living with chronic hepatitis B virus infection: a systematic review and pooled meta-analyses.

  2019cites this paper
• Chronic Viral Hepatitis

  2019cites this paper
• Systematic review of risk factors of hepatocellular carcinoma after hepatitis B surface antigen seroclearance

  2018cites this paper
• Management of Hepatitis B Virus Infection: 2018 Guidelines from the Canadian Association for the Study of Liver Disease and Association of Medical Microbiology and Infectious Disease Canada.

  2018cites this paper
• Natural History of Hepatitis B Virus

  2018cites this paper
• Detection of Hepatitis B Genotypes in HBsAg & HBeAg Carriers

  2018cites this paper
• Protracted HBsAg-aemia in a Patient with Acute Hepatitis B

  2018cites this paper
• 213 – Hepatitis B and Hepatitis D Viruses

  2018cites this paper
• HEPATITIS B VIRUS: A CLINICAL REVIEW

  2018cites this paper
• Viral Factors Affecting Disease Progression

  2018cites this paper
• Epidemiology and Natural History of Chronic Hepatitis B Virus Infection

  2018cites this paper
• Monitoring of patients with chronic hepatitis B without liver cirrhosis while determining the tactics of treatment

  2018cites this paper
• 25 – Hepatitis B Vaccines

  2018cites this paper
• Budget impact analysis on the introduction of a guideline based hepatitis B and C screening into a routine check-up in the German primary care setting

  2018cites this paper
• Затяжная НВsAg-емия у пациента с острым гепатитом В

  2018cites this paper
• Where we are in the fight against Hepatitis B Infection; Trends in Hepatitis B virus seroprevalence in Black Sea Region of Turkey

  2018influential citation
• EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma.

  2018cites this paper
• Correlations between polymorphisms in the uridine diphosphate-glucuronosyltransferase 1A and C-C motif chemokine receptor 5 genes and infection with the hepatitis B virus in three ethnic groups in China

  2017cites this paper
• Treatment of Chronic Hepatitis B: An Update and Prospect for Cure

  2017cites this paper
• Guideline of Prevention and Treatment for Chronic Hepatitis B (2015 Update)

  2017cites this paper
• Systemic and Autoimmune Manifestations of Hepatitis B Virus Infection

  2017cites this paper
• No contribution of lifestyle and environmental exposures to gender discrepancy of liver disease severity in chronic hepatitis b infection: Observations from the Haimen City cohort

  2017cites this paper
• Hepatitis B surface antigen loss and sustained viral suppression in Asian chronic hepatitis B patients: A community‐based real‐world study

  2017cites this paper
• Detection of Mediterranean Hepatitis B in a 45 Years Old Man in Mahdieh Clinical Laboratory, Isfahan, Iran

  2017cites this paper
• Viral Factors Affecting the Clinical Outcomes of Chronic Hepatitis B

  2017cites this paper
• Hepatitis B Virus Infection and Exposure Among Foreign-Born Asian Americans in the U.S.

  2017cites this paper
• Nucleoside analogs treatment delay the onset of hepatocellular carcinoma in patients with HBV-related cirrhosis

  2017cites this paper
• Role of Age and Race in the Risk of Hepatocellular Carcinoma in Veterans With Hepatitis B Virus Infection

  2017cites this paper
• Hepatitis B Virus (HBV) Infection and Hepatocellular Carcinoma- New Insights for an Old Topic.

  2017cites this paper
• Hepatitis B Virus–Related Hepatocellular Carcinoma: Carcinogenesis, Prevention, and Treatment

  2017cites this paper
• Establishing contemporary trends in hepatitis B sero-epidemiology in an Indigenous population

  2017cites this paper
• Nucleoside analogs treatment delay the onset of hepatocellular carcinoma in patients with HBV-related cirrhosis.

  2017cites this paper
• Clearing Persistent Extracellular Antigen of Hepatitis B Virus: An Immunomodulatory Strategy To Reverse Tolerance for an Effective Therapeutic Vaccination

  2016cites this paper
• Arthroplasty in patients with rare conditions Total joint arthroplasty in patients with chronic infectious liver disease

  2016cites this paper
• Revisiting the Natural History of Chronic HBV Infection

  2016cites this paper
• Hepatitis B Virus Infection and Liver Decompensation.

  2016cites this paper
• Ethnic differences in incidence of hepatitis B surface antigen seroclearance in a real‐life multicenter clinical cohort of 4737 patients with chronic hepatitis B infection

  2016cites this paper
• Current role of transient elastography in the management of chronic hepatitis B patients

  2016cites this paper
• Update on occult hepatitis B virus infection

  2016cites this paper
• Treatment of chronic HBV infection in developing countries.

  2016cites this paper
• Frequency of Hepatitis C and Hepatitis B infection in a Tertiary Care Hospital

  2016cites this paper
• HBsAg loss in a New Zealand community study with 28-year follow-up: rates, predictors and long-term outcomes

  2016cites this paper
•  Treatment of chronic HBV infection in developing countries.

  2016cites this paper
• Hepatitis B immunopathogenesis and immunotherapy.

  2016cites this paper
• Hepatitis B virus and its sexually transmitted infection - an update

  2016cites this paper
• Are current screening protocols for chronic hepatitis B virus infection adequate?

  2016cites this paper
• Predictors of hepatitis B e antigen‐negative hepatitis in chronic hepatitis B virus‐infected patients from childhood to adulthood

  2016influential citation
• KASL clinical practice guidelines: management of chronic hepatitis B

  2016cites this paper
• Update on Treatment of Hepatitis B and Prospects for Possible Cure

  2016cites this paper
• An evaluation of entecavir for the treatment of chronic hepatitis B infection in adults

  2016cites this paper
• A genetic variant of the NTCP gene is associated with HBV infection status in a Chinese population

  2016cites this paper
• Natural History of Hepatitis B Virus Infection

  2016cites this paper
• Hepatitis B surface antigen clearance in inactive hepatitis B surface antigen carriers treated with peginterferon alfa-2a.

  2016cites this paper